DexCom shares took a slight tumble after earnings were announced Thursday evening off of strong results. Guidance for the year was upgraded due to growing demand and FDA clearance for the Apple Watch ...

DexCom received FDA approval for its continuous glucose monitoring product, Stelo, to be available over the counter, making it the first OTC CGM product ever. The company has demonstrated robust ...

DexCom's growth rate has been improving, but that hasn't been enough of a reason for investors to buy up the stock. DexCom makes continuous glucose monitoring (CGM) devices, which are crucial for ...

Sometimes the best way to fix a mistake is to double down on it—and that is just what DexCom is doing with its continuous glucose monitors for diabetes patients. It’s a decision that should pay off ...

DexCom , Inc. (NASDAQ:DXCM), a leader in continuous glucose monitoring (CGM) systems for diabetes management with a market ...

Shares have lagged the market this year, partly due to some public image and regulatory issues. DexCom's stock could drop even more if results falls short of revenue expectations. Whatever happens on ...